Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-9966

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression ; volume:38 ; number:1 ; day:16 ; month:12 ; year:2019 ; pages:1-18 ; date:12.2019
Journal of experimental & clinical cancer research ; 38, Heft 1 (16.12.2019), 1-18, 12.2019

Creator: Napolitano, S.
Matrone, N.
Muddassir, A. L.
Martini, G.
Sorokin, A.
De Falco, V.
Giunta, E. F.
Ciardiello, D.
Martinelli, E.
Belli, V.
Furia, M.
Kopetz, S.
Morgillo, F.
Ciardiello, F.
Troiani, T.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13046-019-1497-0

URN: urn:nbn:de:101:1-2020040704110459162137

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Napolitano, S.
Matrone, N.
Muddassir, A. L.
Martini, G.
Sorokin, A.
De Falco, V.
Giunta, E. F.
Ciardiello, D.
Martinelli, E.
Belli, V.
Furia, M.
Kopetz, S.
Morgillo, F.
Ciardiello, F.
Troiani, T.
SpringerLink (Online service)

Other Objects (12)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Related objects

Reset password